Clinical Advances in Diagnosis and Management of Agitation in Alzheimer’s Disease
What exactly is agitation in Alzheimer’s disease? Why is it important? What is the best way to manage it?
Related Articles
What Should Health Professions Trainees Learn About Built Environment Activism?
This article offers examples of connections between built environments and health outcomes and regulation of built environments.
An Emerging Means of Drug Use in Correctional Facilities
This case series discusses the clinical manifestations, management, and outcomes of intoxication from drug-soaked paper strips in a correctional facility population and identifies the specific…
Who Should Contribute to Decisions About Health Care Space Design?
This commentary on a case suggests merits and drawbacks of shared decision-making as one approach to Certificate of Need assessments.
How to design and build health care spaces for the best outcomes
The built environment itself is a kind of medical intervention. Experts examine the role evidence-based design has in improving patient care.
The Annals of Family Medicine Podcast: Innovations from the cutting edge of Family Medicine research | Annals of Family Medicine
Discover innovative insights on family medicine through expert interviews, research highlights, and practical tips in the Annals of Family Medicine Podcast.
Vulnerability to Emotional Contagion May Stress Older Adults
Older adults who are sensitive to the distress of others are more likely to feel anxious or depressed themselves.
5 key healthcare topics for 2025 (and why you should care)
With the new year right around the corner, five Advisory Board experts discuss the healthcare topics they’re most looking forward to diving into in 2025…
Wearables and the Electrophysiology Practice: Challenges and Opportunities
Editor’s Note: Listen to EP Lab Digest’s podcast discussion with Dr. Tarakji — link is included at the end of this article!
FDA Approves Generic Once-Daily GLP-1 RA for Type 2 Diabetes in Pediatric, Adult Patients
The FDA’s approval marks the second generic approval referencing a GLP-1 receptor agonist in as many months for the agency.
PhRMA dues fell almost $100 million as major drugmakers exited
PhRMA’s dues declined after the big drugmakers AbbVie, AstraZeneca, and Teva left the group.
